| Literature DB >> 29035280 |
Inigo Ruiz de Azua1, Giacomo Mancini1, Raj Kamal Srivastava1, Alejandro Aparisi Rey1, Pierre Cardinal2,3, Laura Tedesco4, Cristina Maria Zingaretti5, Antonia Sassmann6, Carmelo Quarta7,8, Claudia Schwitter1, Andrea Conrad1, Nina Wettschureck6, V Kiran Vemuri9, Alexandros Makriyannis9, Jens Hartwig10, Maria Mendez-Lago10, Laura Bindila1, Krisztina Monory1, Antonio Giordano5, Saverio Cinti5, Giovanni Marsicano2,3, Stefan Offermanns6, Enzo Nisoli4, Uberto Pagotto8, Daniela Cota2,3, Beat Lutz1,11.
Abstract
Dysregulated adipocyte physiology leads to imbalanced energy storage, obesity, and associated diseases, imposing a costly burden on current health care. Cannabinoid receptor type-1 (CB1) plays a crucial role in controlling energy metabolism through central and peripheral mechanisms. In this work, adipocyte-specific inducible deletion of the CB1 gene (Ati-CB1-KO) was sufficient to protect adult mice from diet-induced obesity and associated metabolic alterations and to reverse the phenotype in already obese mice. Compared with controls, Ati-CB1-KO mice showed decreased body weight, reduced total adiposity, improved insulin sensitivity, enhanced energy expenditure, and fat depot-specific cellular remodeling toward lowered energy storage capacity and browning of white adipocytes. These changes were associated with an increase in alternatively activated macrophages concomitant with enhanced sympathetic tone in adipose tissue. Remarkably, these alterations preceded the appearance of differences in body weight, highlighting the causal relation between the loss of CB1 and the triggering of metabolic reprogramming in adipose tissues. Finally, the lean phenotype of Ati-CB1-KO mice and the increase in alternatively activated macrophages in adipose tissue were also present at thermoneutral conditions. Our data provide compelling evidence for a crosstalk among adipocytes, immune cells, and the sympathetic nervous system (SNS), wherein CB1 plays a key regulatory role.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29035280 PMCID: PMC5663356 DOI: 10.1172/JCI83626
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808